Secukinumab vs Adalimumab for The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from A Brazilian Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2978
https://www.valueinhealthjournal.com/article/S1098-3015(17)33312-0/fulltext
Title :
Secukinumab vs Adalimumab for The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from A Brazilian Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33312-0&doi=10.1016/j.jval.2017.08.2978
First page :
A938
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2724